Gastroparesis Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Rise in the Prevalence of Idiopathic Gastroparesis
   3. Market Restraints
      1. Limited Treatment Options
      2. Diagnostic Challenges
   4. Market Opportunities
      1. Increase in the Surgeries Can Cause Post-Operative Gastroparesis
   5. Market Trends
      1. Rising Demand for Minimally Invasive Therapies
      2. Integration of Digital Health Solutions
5. MARKET SEGMENTATION
   1. By Type
      1. Idiopathic
      2. Diabetic
      3. Post- Surgical
      4. Others
   2. By Drug Class
      1. Prokinetic Drugs
      2. Antiemetics
      3. Botulinum Toxin Injection
      4. Antidepressants
      5. Others
   3. By Treatment
      1. Jejunostomy
      2. Gastric Electric Stimulation
      3. Parenteral Nutrition
      4. Diabetic Gastroparesis
      5. Chronic Gastroparesis
      6. Idiopathic Gastroparesis
      7. Post-Operative Gastroparesis
   4. By Distribution Channel
      1. Retail Pharmacies
      2. Hospital Pharmacies
      3. Others
   5. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Abbott
      2. Amneal Pharmaceuticals LLC
      3. ALLERGAN
      4. Annora Pharma Pvt
      5. AbbVie Inc
      6. CAIRN DIAGNOSTICS
      7. Bristol-Myers Squibb Company
      8. bioMérieux, Inc
      9. Bio-Rad Laboratories, Inc
      10. Bayer AG
      11. CAIRN DIAGNOSTICS
      12. Evoke Pharma
      13. Lupin Pharmaceuticals Inc.
      14. Endologic
      15. Medtronic
      16. Novartis AG
      17. Neurogastrx, Inc.
      18. Pfizer Inc
      19. Takeda Pharmaceutical Company Limited.
      20. Theravance Biopharma
      21. Thermo Fisher Scientific
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Gastroparesismarket?

The global market of Gastroparesis is projected to reach USD 11,895.83Mn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Gastroparesismarket?

The global Gastroparesis market has an estimated annual growth rate of 3.6% .

Q.3. What are the recent trends of Gastroparesismarket?

Rising demand for minimally invasive therapies and integration of digital health solutions are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Gastroparesis?

The major companies profiled in this report include Abbott, Amneal Pharmaceuticals LLC, ALLERGAN, Annora Pharma Pvt., AbbVie Inc, Bristol-Myers Squibb Company, bioMérieux, Inc, Bio-Rad Laboratories, Inc, Bayer AG, CAIRN DIAGNOSTICS, Evoke Pharma, Lupin Pharmaceuticals Inc., Endologic, Medtronic, Novartis AG, Neurogastrx, Inc., Pfizer Inc, Takeda Pharmaceutical Company Limited., Theravance Biopharma, Thermo Fisher Scientific, among others.

Q.5. Which region is estimated to held highest CAGR inGastroparesismarket?

North America is estimated to hold biggest share in the market for Gastroparesis.